Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when BridgeBio Oncology Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get BBOT alerts

About Pedro J. Beltran, Ph.D.

Pedro J. Beltran, Ph.D. is recorded as Board Member and CEO at BridgeBio Oncology Therapeutics, Inc. (BBOT) since April 20, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 29, 2026 that Pedro J. Beltran, Ph.D. was appointed President and Chief Executive Officer, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 29, 2026 that Pedro J. Beltran, Ph.D. was appointed member of the Company's Board of Directors and as a Class III director, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro Beltran, Ph.D. (CEO and Board Member), Neil Kumar, Ph.D. (Chairman) and 7 others.

“Eli Wallace, Ph.D. resigned from his position as a member of the Company's Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company's President and Chief Executive Officer, effective on April 20, 2026.”
BridgeBio Oncology Therapeutics, Inc. Form 8-K, filed April 29, 2026 · Read the filing
“Eli Wallace, Ph.D. resigned from his position as a member of the Company's Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company's President and Chief Executive Officer, effective on April 20, 2026.”
BridgeBio Oncology Therapeutics, Inc. Form 8-K, filed April 29, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at BridgeBio Oncology Therapeutics, Inc.

Recent activity